Patents by Inventor Marga Bott

Marga Bott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF INDUCING AND PREVENTING NEUROFIBROMATOSIS IN SCHWANN CELLS
    Publication number: 20160177261
    Abstract: The invention provides a method of inducing neurofibromatosis type 2 (NF2) in Schwann cells. The method comprises contacting the cells with laminin-1 so as to bind ?6?1 integrin sufficiently to activate endogenous kinase Cdc42-Pak; and phosphorylating Schwannomin-S518 in the cells by the activated kinase, effectively inactivating. Schwannomin's tumor suppressor activity and allowing proliferation of subconfluent Schwann cells, thereby modeling NF2. The invention also includes a method of preventing a Schwann cell from forming a tumor by contacting the cell with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from ErB2, ErB3, ?1 integrins and combinations thereof, so as to prevent phosphorylation of Schwannomin-S815 by one or more endogenous kinases.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 23, 2016
    Applicant: University of Central Florida Research Foundation, Inc.
    Inventors: Cristina Fernandez-Valle, Courtney Thaxton, Jorge Lopera, Marga Bott
  • Methods of inducing and preventing neurofibromatosis in Schwann cells
    Patent number: 9226920
    Abstract: The invention provides a method of inducing neurofibromatosis type 2 (NF2) in Schwann cells. The method comprises contacting the cells with laminin-1 so as to bind ?6?1 integrin sufficiently to activate endogenous kinase Cdc42-Pak; and phosphorylating Schwannomin-S518 in the cells by the activated kinase, effectively inactivating Schwannomin's tumor suppressor activity and allowing proliferation of subconfluent Schwann cells, thereby modeling NF2. The invention also includes a method of preventing a Schwann cell from forming a tumor by contacting the cell with an amount of tyrphostin AG825 sufficient to inhibit a receptor selected from ErB2, ErB3, ?1 integrins and combinations thereof, so as to prevent phosphorylation of Schwannomin-S815 by one or more endogenous kinases.
    Type: Grant
    Filed: June 12, 2008
    Date of Patent: January 5, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Cristina Fernandez-Valle, Courtney Thaxton, Jorge Lopera, Marga Bott